Categories: Business

Serum Institute may launch COVID-19 vaccine by June, may cost up to one thousand rupees


Serum Institute to begin trials of Oxford's COVID-19 vaccine candidate by Aug-end

new Delhi. The Serum Institute of India said on Tuesday that it will begin testing the Kovid-19 vaccine developed by Oxfod University and AstraZeneca by the end of August. The company said that efforts are being made to get the necessary approvals to test this vaccine on 5000 Indian patients. The company claims that if everything goes well, it will launch this vaccine in the market by June 2021.

Adar Poonawala, CEO of the world's largest vaccine producer company, said the company would spend $ 200 million to make 300 million doses, which is a risk. Because we have to do this before we get the necessary approval to launch the vaccine. He claimed that the vaccine's test report was expected to come out by the end of this year. Oxfod University announced on Monday that the vaccine has yet to yield satisfactory results. Poonawala said that Oxfod University has tied up with Serum Institute in India and 60 other countries to supply this vaccine. Under this, 3 billion doses will be manufactured.

Adar Poonawala said that the price of Kovid-19 vaccine will be kept at a minimum. He said that initially no profit will be made on this vaccine. Poonawala claimed that the price of Kovid-19 in India could be Rs 1000 or even less. Poonawalla said that before that there was no hard work for any vaccine. We are unable to pay attention to many products due to the corona vaccine. Given the growing crisis of the corona epidemic, it seems that the vaccine has to be focused on for the next two-three years, as the whole world is battling the corona virus.

Poonawala said that after getting the approval, this vaccine will be tested on 4-5 thousand people in Pune and Mumbai. These people will be corona infected. He said that this vaccine will be tested on elderly and health workers in India as well. Along with the testing process, the company will also apply for a special approval to start manufacturing the vaccine in the country. This would put the company at a commercial risk. If the vaccine fails in the last phase, the company will incur a loss of about $ 200 million.

After getting the special approval, the company will produce 7 crore doses per month from October and plans to increase the number to 10 crore per month by December. Poonawala said that if everything goes according to plan, then the third phase test will take two months after injecting the patients and the vaccine may get the final approval by November. In this scenario the vaccine may be launched in the first or second quarter of next year.

This post was published on July 22, 2020 9:42 am

Content Team

Recent Posts

ICICI Bank raised Rs 15,000 crore from QIP, issued 41.89 crore shares to investors at Rs 358

Photo: BUSINESS INSIDER INDIA ICICI Bank closes QIP; garners Rs 15,000 cr from share sale new Delhi. ICICI Bank, the…

Jio-RCom spectrum sharing deal not connected with AGR liability | Jio-RCom spectrum partnership deal not linked to AGR liability, will not pay

Photo: YAHOO FINANCE Jio-RCom spectrum sharing deal not connected with AGR liability new Delhi. Reliance Jio's four-year-old telecom spectrum partnership…

Google Pixel 5 May Only Launch in XL Variant will be launched in India this year, only Google Pixel XL, phone will not be launched on small screen

Photo: GADGET 360 Google Pixel 5 May Only Launch in XL Variant San Francisco. Google is reportedly planning to launch…